



National Transplant Consensus Guidance on COVID-19 Vaccine

Introduction

The following document provides expert consensus guidance that can be used by provincial organ donation organizations and regional transplant and donation programs to guide the management of COVID-19 vaccination in transplant recipients in light of the pandemic. It is understood that each organization, program, and jurisdiction will develop their own policies.

Since the situation is rapidly evolving, going forward, regular teleconferences will be held with national experts to discuss and update this consensus guidance. These discussions, and the consensus itself, will continue to be informed by recommendations from the Canadian Society for Transplantation, Canadian Blood Services' advisory committees, Health Canada, Public Health Agency of Canada, WHO, provincial agencies, and international partners (including UK and Spain).

This document was last updated on **January 23rd, 2021** and will continue to be updated as new evidence and information becomes available.

What do we know about COVID-19 and transplant recipients?

COVID-19 is a disease caused by the SARS-CoV-2 virus that is predominantly a respiratory virus but can cause multi-system disease. Several organ transplant recipients have contracted COVID-19 and symptoms have ranged from mild disease to the need for ICU care and death. Whether COVID-19 is more severe due to immunosuppression is unclear; however, many transplant patients also have other comorbid conditions such as advanced age, chronic kidney disease, diabetes, and heart/lung disease that put them at increased risk of severe COVID-19 disease. Lung transplant patients also seem to be at particularly high risk of severe disease.

What is the status of COVID-19 vaccines in Canada?

There are several formulations of the COVID-19 vaccine in various stages of development and/or approval. Two vaccines (Pfizer/BioNTech and Moderna vaccine) have been authorized for use by Health Canada. Both vaccines are composed of mRNA in a lipid nanoparticle and have specific storage conditions. In total, approximately 70,000 persons participated in placebo-controlled phase 3 trials with these vaccines. The Pfizer vaccine has an efficacy of 95% in immunocompetent persons and is for use in persons 16 years of age and older. The Moderna vaccine has a 94.1% efficacy and is for persons 18 years of age and older. Both vaccines are given as a two dose series. Other vaccines, including the University of Oxford/AstraZeneca adenovirus vector vaccine (62 to 90% efficacy in a phase 3 trial) and Johnson & Johnson vaccine, are also under consideration and may be authorized in Canada in the future.

What are the side effects of COVID-19 vaccine?

Local and systemic side effects can occur after vaccine. These include local tenderness, swelling, and erythema. Relatively common systemic symptoms include fever, myalgias, and headache. In the Pfizer vaccine trial, systemic symptoms were more common in younger age groups and after the second vaccine dose. Similarly, in



the Moderna vaccine trial, there were more systemic events after the second dose. Systemic symptoms are similar to COVID-19 disease so patients receiving vaccine should be counseled on the possibility of these symptoms occurring in the first few days after each vaccine dose.

What data are available about the COVID-19 vaccine in transplant recipients?

Currently, there are no efficacy, immunogenicity, or safety data available for transplant patients with any COVID-19 vaccine. Transplant recipients were not enrolled in phase 3 studies of vaccine. However, with the licensure of vaccine in many countries, more information is expected.

Can transplant patients receive the COVID-19 vaccine?

Although further data are needed, the opinion of experts is that transplant patients may receive the vaccine (see below). Experts believe that based on the mechanism of action of mRNA vaccine, there is no reason to suspect that adverse events will be any different than in the general population. Based on expert opinion, the potential benefits of vaccine likely outweigh theoretical risks. mRNA leads to a vaccine-specific immune response and the generation of alloimmunity or rejection following vaccination is unlikely based on the mechanism of the vaccine, and broad experience with other vaccines in the transplant population. For optimum vaccine efficacy, it is suggested that:

- When possible, vaccine be administered in the pre-transplant setting with the final dose at least 1-2 weeks prior to transplant
- It is not necessary to put a patient on hold for transplant while waiting for vaccination
- In post-transplant patients, wait at least 1 month after transplant to provide the vaccine regardless of induction therapy.
- Ideally, the full 2-dose series should be given (Pfizer or Moderna vaccine) at the recommended interval. If the patient undergoes transplantation between the first and second doses, provide the second dose at 1 month after transplant. Additional doses are not recommended.
- In patients undergoing active treatment for acute rejection, vaccination can be deferred for a 1-month period.
- Avoid giving vaccine for at least 3 months after rituximab for improved efficacy
- If a patient has had COVID-19 before, wait 90 days from diagnosis and symptom recovery before giving COVID-19 vaccine.
- Since there are no vaccine coadministration studies, avoid giving other vaccines within 2 weeks of the COVID-19 vaccine dose.
- Vaccine should not be given to patients that have had an anaphylactic reaction to a known component of the vaccine (i.e., polyethylene glycol)
- Since efficacy is expected to be lower than the general population, it is strongly recommended that patients continue to practice infection control measures. In addition, household contacts of the transplant recipient should also be vaccinated when possible.

When will the vaccine be available for transplant patients?



In Canada, the priority groups are currently long-term care residents/workers, healthcare workers, and indigenous populations. When there is sufficient vaccine supply, other groups will also be identified and eventually the vaccine will be rolled out to the general population. Thus, it may well be March or April 2021 when vaccination can be given to transplant patients. However, it is possible that in some provinces transplant patients could be prioritized but this is currently uncertain. Additional vaccines may be authorized in the future and we may also have additional information about adverse event profiles. It is recognized that transplant patients may also be working/residing in long term care and/or be health care workers. Thus, vaccine will be available for these groups sooner.

What about pediatric transplant patients?

The vaccine is currently not approved for children under 16 years of age, but once approved, we expect similar recommendations to apply to pediatric transplant recipients. Studies are currently ongoing for ages 12 and up.

What are the national and international recommendations?

The CDC Advisory Committee on Immunization Practices (ACIP; U.S.) and the Joint Committee on Vaccination and Immunisation (JCVI; U.K.) has stated that vaccine can be given to immunocompromised population when it becomes available. The JCVI has listed patients with a transplant as being a prioritized vulnerable population. The AST (American Society of Transplantation) and ISHLT (International Society for Heart and Lung Transplantation) have also recommended COVID-19 vaccine to be given to transplant patients when available. Health Canada and FDA have not contraindicated the vaccine for immunocompromised although have stated that there are no data on efficacy and adverse events in this population.

The National Advisory Committee on Immunization in Canada has updated its recommendations and stated that vaccination may be given to immunocompromised patients after considering the risk vs. benefits and letting individuals know that data on efficacy and safety are lacking. Efficacy may be lower in the immunosuppressed state and immunocompromised patients should continue to practice infection control measures against COVID-19.

Summary

Given that: (a) COVID can cause serious illness in a transplant recipient, (b) transplant recipients often have comorbidities, (c) the mechanism of action of vaccine is specific, and (d) transplantation is not a contraindication to COVID vaccine according to Health Canada, we recommend that vaccine may be given to the pre- and post-transplant patient population when it is available to them. Based on expert opinion, we recommend that the potential benefits of vaccine outweigh any theoretical risks or concerns about immunogenicity. *Due to the severity of COVID in this population, we also recommend that transplant patients be prioritized for vaccination.* Transplant patients should be made aware of the lack of safety and efficacy data and encouraged to report any adverse events.

Disclaimer



The guidance provided is not meant to replace clinical judgement. The field is also rapidly evolving and as such the guidance will likely change over time. Any clinical decisions should be made in consideration of the latest available information.

Endorsement

These guidelines were produced by the UHN Ajmera Transplant Center and endorsed by the Canadian Society of Transplantation.



References

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PMID: 33301246.
2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2020 Dec 30:NEJMoa2035389. doi: 10.1056/NEJMoa2035389. Epub ahead of print. PMID: 3337860.
3. Voysey M, Clemens SAC, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: *Lancet*. 2021 Jan 9;397(10269):98. PMID: 33306989.
4. <https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020> (accessed Jan 23, 2021)
5. <https://www.myast.org/covid-19-information> (accessed Jan 23, 2021)
6. Advisory Committee on Immunization Practices – Live discussion and vote – Dec 12, 2020
7. <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html#a7>
8. <https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-pm1-en.pdf>
9. <https://covid-vaccine.canada.ca/info/pdf/moderna-covid-19-vaccine-pm1.pdf>
10. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74543a-eng.php>
11. <https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna.html#a11>